Goyal Sonal, Kumar Ajit, Sharma Ravi Shankar, Goyal Divakar, Singh Girish Kumar
Department of Anaesthesiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Indian J Anaesth. 2022 Jul;66(7):485-497. doi: 10.4103/ija.ija_154_22. Epub 2022 Jul 22.
Cryoneurolysis, a neuroablative technique, is used in the event of failure of conservative treatment in chronic pain conditions. To date, no systematic review has been published to demonstrate its effectiveness in managing chronic non-cancer pain. Therefore, this review was done to ascertain the efficacy of cryoneurolysis and describe its role in chronic non-cancer pain management.
We searched PubMed, Cochrane, Embase, Scopus, and Google Scholar databases for articles published between January 2011 and September 2021. Two independent reviewers extracted the data from the included studies. Assessment of risk of bias of included randomised controlled trials (RCTs) was done using RevMan 5.4.1 software and Newcastle-Ottawa scale was used for non-randomised studies.
Ten studies enroling a total of 425 patients were included in the qualitative analysis. Eight studies were assessed quantitatively. RCTs were found only for cervicogenic headache and knee osteoarthritis management. The rest of the included studies were prospective non-controlled and retrospective studies. A significant pain reduction was seen at seven-day [Standardised Mean Difference (SMD) 1.77 (1.07, 2.46)], < 0.00001, I = 79%), one-month (SMD 3.26 [2.60, 3.92], < 0.00001, I = 45%), three-month (SMD 2.58 [1.46, 3.70], < 0.00001, I = 93%), six-month (SMD 2.38 [0.97, 3.79], = 0.001, I = 86%) follow-ups. Improved disability and no serious complications were noted.
Cryoneurolysis appeared to be effective in pain alleviation in refractory painful conditions for up to six months. It is safe and well-tolerated with an excellent safety profile but the quality of evidence is limited by substantial heterogeneity between trials. Therefore, more comparative clinical trials on a larger sample size are needed to provide more concrete evidence.
冷冻神经lysis术是一种神经毁损技术,用于慢性疼痛疾病保守治疗失败的情况。迄今为止,尚未发表系统评价来证明其在治疗慢性非癌性疼痛方面的有效性。因此,进行本评价以确定冷冻神经lysis术的疗效,并描述其在慢性非癌性疼痛管理中的作用。
我们在PubMed、Cochrane、Embase、Scopus和谷歌学术数据库中检索了2011年1月至2021年9月发表的文章。两名独立的评审员从纳入的研究中提取数据。使用RevMan 5.4.1软件对纳入的随机对照试验(RCT)进行偏倚风险评估,对于非随机研究使用纽卡斯尔-渥太华量表。
定性分析纳入了10项研究,共425例患者。8项研究进行了定量评估。仅发现了关于颈源性头痛和膝骨关节炎治疗的随机对照试验。其余纳入的研究为前瞻性非对照研究和回顾性研究。在7天(标准化均数差(SMD)1.77 [1.07, 2.46],<0.00001,I² = 79%)、1个月(SMD 3.26 [2.60, 3.92],<0.00001,I² = 45%)、3个月(SMD 2.58 [1.46, 3.70],<0.00001,I² = 93%)、6个月(SMD 2.38 [0.97, 3.79],P = 0.001,I² = 86%)随访时疼痛显著减轻。观察到残疾改善且无严重并发症。
冷冻神经lysis术在缓解难治性疼痛状况的疼痛方面似乎有效,长达6个月。它安全且耐受性良好,具有出色的安全性,但证据质量受到试验间显著异质性的限制。因此,需要更多更大样本量的比较性临床试验来提供更确凿的证据。